<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="309">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04339413</url>
  </required_header>
  <id_info>
    <org_study_id>WN41874</org_study_id>
    <nct_id>NCT04339413</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)</brief_title>
  <official_title>An Open-Label, Multicenter, Rollover Study to Evaluate the Safety and Tolerability of Long-Term Administration of Gantenerumab in Participants With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, rollover study to evaluate the safety and tolerability of&#xD;
      long-term administration of gantenerumab in participants with AD. All participants who have&#xD;
      completed the open-label extensions (OLEs) of Studies WN25203 or WN28745 will be eligible to&#xD;
      participate in Part 1 of this study. Of these, participants who complete Week 104 visit in&#xD;
      Part 1 will be eligible for Part 2 of this study. Participants will continue receiving&#xD;
      open-label gantenerumab by subcutaneous (SC) injection every four weeks (Q4W) at the same&#xD;
      dose as administered in the parent studies (part 1)/ Week 104 visit (part 2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 22, 2020</start_date>
  <completion_date type="Anticipated">May 27, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 27, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 4 weeks after the last dose of study drug (Baseline [Day 1] up to Week 212)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Columbia-Suicide Severity Rating Scale (C-SSRS) Score</measure>
    <time_frame>Baseline (Day 1) up to Week 208</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Confirmed by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline (Day 1) up to Week 208</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Amyloid-Related Imaging Abnormalities-Haemosiderin deposition (ARIA-H) Confirmed by MRI</measure>
    <time_frame>Baseline (Day 1) up to Week 208</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Anti-drug Antibody (ADA) to Gantenerumab</measure>
    <time_frame>Baseline (Day 1) up to Week 208</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Injection-Site Reactions</measure>
    <time_frame>Up to 4 weeks after the last dose of study drug (Baseline [Day 1] up to Week 212)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Treatment due to AEs</measure>
    <time_frame>Baseline (Day 1) up to Week 208</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Gantenerumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will continue receiving open-label gantenerumab by subcutaneous (SC) injection every four weeks (Q4W) up to Week 208.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gantenerumab</intervention_name>
    <description>Gantenerumab will be administered as SC injection Q4W</description>
    <arm_group_label>Gantenerumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Part 1: Participants who completed the open-label extensions (OLEs) of studies WN25203&#xD;
             or WN28745 will be eligible to participate in Part 1 of the study&#xD;
&#xD;
          -  Part 2: All participants who have completed Week 104 visit in Part 1 will be eligible&#xD;
             for Part 2 of the study&#xD;
&#xD;
          -  For Part 1 and Part 2:&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraceptive methods that result in a failure rate&#xD;
             of &lt;1% per year during the treatment period and for at least 16 weeks after the last&#xD;
             dose of study drug&#xD;
&#xD;
          -  Agreement to not donate blood or blood products for transfusion for the duration of&#xD;
             the study and for 1 year after final dose of study drug&#xD;
&#xD;
          -  Availability of a person ('caregiver') who in the investigator's judgement, has&#xD;
             frequent and sufficient contact with the participant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prematurely discontinued from the OLEs of studies WN25203 or WN28745 or from study&#xD;
             drug for any reason&#xD;
&#xD;
          -  Any medical condition that may jeopardize the participant's safety if he or she&#xD;
             continues to receive study treatment&#xD;
&#xD;
          -  If the participant is unlikely to benefit from gantenerumab therapy, based on disease&#xD;
             progression or other factors, or if study participation is otherwise not in the&#xD;
             participant's best interest&#xD;
&#xD;
          -  Any investigational treatment other than gantenerumab during or since completion of&#xD;
             the OLEs of studies WN25203 or WN28745&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Evidence of disseminated leptomeningeal hemosiderosis (i.e., more than three focal&#xD;
             leptomeningeal hemosiderosis)&#xD;
&#xD;
          -  Evidence of intracerebral macrohemorrhage&#xD;
&#xD;
          -  Part 2: Participants who have been discontinued from Part 1 of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner Sun Health Research Insitute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Neuroscience Research Medical Group, Inc</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelerated Enrollment Solutions</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613-4706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioclinica The Villages</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Michigan University Homer Stryker M.D. School of Medicine Center for Clinical Research</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alzheimer's Memory Center</name>
      <address>
        <city>Matthews</city>
        <state>North Carolina</state>
        <zip>28105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central States Research</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Clinic PC</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senior Adults Specialty Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Neurologia Bs As</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1426ANZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital; Neurology</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre</name>
      <address>
        <city>Heidelberg West</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centricity Research</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3S 1N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>True North Clinical Research-Halifax</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3S 1N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawartha Centre - Redefining Healthy Aging</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9H 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Memory Program</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpha Recherche Clinique</name>
      <address>
        <city>Quebec</city>
        <zip>G3K 2P8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Especialidades Medicas LYS</name>
      <address>
        <city>Santiago</city>
        <zip>7560356</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Hukommelsesklinikken</name>
      <address>
        <city>Koebenhavn Oe</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuovo Ospedale Civile S. Agostino-Estense; Clinica Neurologica - Dipartimento di Neuroscienze</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Spedali Civili; Scienze Neurologiche</name>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS &quot;Centro S. Giovanni di Dio&quot; Fatebenefratelli -UO Alzheimer</name>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Multimedica Santa Maria; Unita' Di Neurologia</name>
      <address>
        <city>Castellanza</city>
        <state>Lombardia</state>
        <zip>21053</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione San Raffaele Del Monte Tabor; Dipartimento Di Neurologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Hakuyokai Kashiwado Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8656</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Urayasu Hospital; Neurology</name>
      <address>
        <city>Chiba</city>
        <zip>279-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Hiroshima-Nishi Medical Center</name>
      <address>
        <city>Hiroshima</city>
        <zip>739-0696</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Hospital (Seoul)</name>
      <address>
        <city>Seoul</city>
        <zip>07804</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mexico Americano</name>
      <address>
        <city>Guadalajara</city>
        <state>Mexico CITY (federal District)</state>
        <zip>44610</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario; Dr. Jose E. Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LEON</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AVIX Investigación Clínica S.C</name>
      <address>
        <city>Monterrey</city>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Research Center B.V</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 GN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ NEURO-KARD Ilkowski i Partnerzy Sp. Partn. Lek</name>
      <address>
        <city>Poznań</city>
        <zip>61-853</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Przychodnia Specjalistyczna PROSEN</name>
      <address>
        <city>Warszawa</city>
        <zip>01-231</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne NeuroProtect</name>
      <address>
        <city>Warszawa</city>
        <zip>01-684</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Institution of Healthcare City Geriatric Medico-Social Center</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSMEI HPE &quot;Military Medical Academy n.a. S.M.Kirov&quot;of Minist</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche; Servicio de Neurología</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua De Terrasa; Servicio de Neurologia</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar; Servicio de Neurologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación ACE; Servicio de Neurología</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre; Servicio de Neurologia</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset; Servicio de Neurologia</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Fe; Servicio de Neurologia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Felix Platter-Spital Medizin Geriatrie</name>
      <address>
        <city>Basel</city>
        <zip>4002</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University Istanbul School of Medicine; Neurology</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul University Medicine Faculty; Noroloji Departmani</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ondokuz Mayis University School of Medicine; Neurology</name>
      <address>
        <city>Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Llandough Hospital; Llandough Hospital Memory Team 3rd Floor Academic Building</name>
      <address>
        <city>Cardiff</city>
        <zip>CF64 2XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial Memory Unit, Charing Cross Hospital; Level 10 West, Department of Neurosciences</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campus for Ageing &amp; Vitality; Clincal Ageing Research Unit</name>
      <address>
        <city>Newcastle</city>
        <zip>NE4 5PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollins Park Hospital</name>
      <address>
        <city>Warrington</city>
        <zip>WA2 8WA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Denmark</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>September 23, 2022</last_update_submitted>
  <last_update_submitted_qc>September 23, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

